FOLD Stock UPDATES Amicus Therapeutics (FOLD) 5.82 10/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amicus Therapeutics (FOLD) 5.82 $FOLD

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 21.21 (-0.40), SNY: 52.15 (+0.37), FOLD: 5.82 (-0.12)

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
GlobeNewswire - Sun Oct 19, 6:00PM CDT
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)
FOLD: 5.82 (-0.12)

Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 30, 8:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.
FOLD: 5.82 (-0.12)

Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
NVAX: 4.99 (-0.02), DNDN: 1.10 (-0.03), ARNA: 4.16 (-0.01), FOLD: 5.82 (-0.12), EXEL: 1.60 (-0.05)

Why Amicus Therapeutics (FOLD) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:36AM CDT
Amicus Therapeutics (FOLD) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
FOLD: 5.82 (-0.12)

Amicus Therapeutics (FOLD) Stock Rises on High Volume
at The Street - Thu Aug 28, 11:40AM CDT
Amicus Therapeutics (FOLD) nearly touched a 52-week high of $7.40 on Thursday as the stock continued to rise on high volume.
FOLD: 5.82 (-0.12)

The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the RadioShack Corp. (NYSE:RSH-Free Report), Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report), Shire (Nasdaq:SHPG-Free Report) and Gilead Sciences Inc. (Nasdaq:GILD-Free Report).
GILD: 106.67 (+4.46), RSH: 0.97 (-0.07), FOLD: 5.82 (-0.12)

Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
KITE: 35.75 (+1.44), ACHN: 11.43 (+0.44), ITMN: 73.89 (-0.02), ALXN: 174.47 (+6.27), PBYI: 228.08 (+2.55), FOLD: 5.82 (-0.12), CELG: 94.97 (+2.97)

Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
ENDP: 63.73 (+2.29), GILD: 106.67 (+4.46), AMGN: 144.09 (+6.58), FOLD: 5.82 (-0.12)

Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
at The Street - Mon Aug 25, 1:18PM CDT
These five stocks all have the potential to be acquired for a 100% premium or more, and each are heavily owned by a top hedge fund or billionaire...
SGEN: 35.31 (+0.06), ITMN: 73.89 (-0.02), RPRX: 6.02 (-0.21), FOLD: 5.82 (-0.12), DYAX: 10.19 (-0.01), ARRY: 3.48 (+0.01)

Clinical Trial Results, Change of Corporate Name, New Products, and Completion of Acquisition - Research Reports on GSK, Amicus, WellPoint, IDEXX and Endo
PR Newswire - Mon Aug 25, 7:40AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline PLC (NYSE: GSK), Amicus Therapeutics, Inc. (NASDAQ: FOLD), WellPoint Inc. (NYSE: WLP), IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5933-100free.
ENDP: 63.73 (+2.29), IDXX: 124.40 (+3.82), GSK: 43.63 (+0.02), WLP: 120.43 (+4.20), FOLD: 5.82 (-0.12)

Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Aug 22, 1:14PM CDT
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 5.82 (-0.12)

Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day
PR Newswire - Fri Aug 22, 9:20AM CDT
Zacks Equity Research highlights Epizyme (Nasdaq:EPZM-Free Report) as the Bull of the Day and Panera (Nasdaq NRA-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report) and Shire (Nasdaq:SHPG-Free Report).
FOLD: 5.82 (-0.12)

Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
GILD: 106.67 (+4.46), SHPG: 185.80 (+1.21), SNY: 52.15 (+0.37), FOLD: 5.82 (-0.12)

Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 20.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 20% on the day.
CBPO: 52.11 (+0.11), CBM: 17.88 (+0.14), GILD: 106.67 (+4.46), FOLD: 5.82 (-0.12)

Can the Rally in Amicus Therapeutics (FOLD) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:03AM CDT
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue?
FOLD: 5.82 (-0.12)

SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 20.35% Gain
Comtex SmarTrend(R) - Wed Aug 20, 4:00PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $5.02 to a high of $5.99. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $4.70 on volume of 33.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 5.82 (-0.12)

Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today
at The Street - Wed Aug 20, 9:29AM CDT
Amicus Therapeutics (FOLD) surged to a 52-week high on Wednesday after the company announced its potential Fabry disease treatment drug migalastat met its primary endpoints in a late-stage study.
FOLD: 5.82 (-0.12)

Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Wed Aug 20, 9:12AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amicus Therapeutics , a clinical-stage...
SNY: 52.15 (+0.37), FOLD: 5.82 (-0.12)

Amicus Therapeutics Has Returned 111.6% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Aug 20, 9:10AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on May 30th, 2014 at $2.42. In approximately 3 months, Amicus Therapeutics has returned 111.57% as of today's recent price of $5.12.
FOLD: 5.82 (-0.12)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 86

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 30

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 101

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 62

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading

Top 5 Most Recently Viewed Articles

Aptiv Plans Strategic Split to Strengthen Innovation and Growth

Updated Category News Views 783

Aptiv's Transformative Separation Announcement Aptiv PLC (NYSE: APTV), a pioneering technology company focused on creating a safer and more connected future, has officially unveiled plans to separate its Electrical Distribution Systems (EDS) business. This strategic decision, unanimously approved by the Board of Directors, sets the stage for both Aptiv and EDS to operate...

Continue Reading
e& Reports Strong Q3 2025 with Record Revenue and Growth

Updated Category News Views 364

Impressive Growth for e& in Q3 2025 e& has unveiled its Q3 2025 financial summary, showcasing robust growth with consolidated revenues soaring to AED 18.6 billion. This marks an impressive year-over-year growth of 29.2%. The momentum isn't just limited to the quarter; for the first nine months of 2025, the company reported consolidated revenues of AED 53.5 billion,...

Continue Reading
PARRIS Law Firm Achieves Prestigious Trial Awards for 2024 Success

Updated Category News Views 242

Acknowledging PARRIS Law Firm's Impressive Recognition in 2024 PARRIS Law Firm, renowned for its excellence in trial advocacy, has just earned multiple accolades from Top Verdict for its remarkable performances in 2024. With several No. 1 verdicts in various categories, this year marks another milestone for the firm as it stands tall among California's premier legal...

Continue Reading
Insights into the Latest Riksbank Certificate Auction Results

Updated Category News Views 232

Overview of the Riksbank Certificate Auction The recent auction conducted by the Riksbank has revealed significant details regarding certificate sales that are vital for investors and market analysts. The auction concluded successfully, showcasing the Riksbank's strategies and market engagement. Auction Details and Financial Impact Key Dates and Interest Rates The auction...

Continue Reading
Alamar Biosciences Unveils Advanced NULISAqpcr Custom Assay Kit

Updated Category News Views 205

Alamar Biosciences Introduces the NULISAqpcr™ Custom Assay Development Kit Alamar Biosciences has unveiled a significant innovation in the field of precision proteomics with the launch of the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking product allows researchers to develop highly sensitive biomarker assays tailored to their specific research needs....

Continue Reading